Can tremelimumab be marketed?

Tremelimumab (tremelimumab) was first approved by the U.S. Food and Drug Administration (FDA) in October 2022. Approved by the European Medicines Agency (EMA) in 2022, it is an emerging cancer immunotherapy drug. It is a prescription drug and has not yet been marketed in China. Therefore, it has not been included in the medical insurance list. Domestic patients cannot yet purchase this drug. The U.S. version of temsitumumab the original drug has been on the market overseas for a short time and is sold under the trade name Imjudo. The price is not yet clear, and there are currently no generic versions of temsitumumab produced and launched. For specific prices and drug details, please consult a medical consultant.